Regeneron's Phase III trial investigated cemdisiran and pozelimab as both monotherapies and in combination in gMG.
New therapies are changing what is possible in generalised myasthenia gravis care, yet unequal access across Europe continues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results